中国循证医学杂志
中國循證醫學雜誌
중국순증의학잡지
CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE
2003年
1期
26-33
,共8页
吴泰相%Harrison Roger%刘关键%郝保清%周礼鲲%魏家富%王覃%倪娟%段鑫%乔杰奇%陈小燕%郑洁
吳泰相%Harrison Roger%劉關鍵%郝保清%週禮鯤%魏傢富%王覃%倪娟%段鑫%喬傑奇%陳小燕%鄭潔
오태상%Harrison Roger%류관건%학보청%주례곤%위가부%왕담%예연%단흠%교걸기%진소연%정길
通心络胶囊%疗效和副效%Cochrane系统评价
通心絡膠囊%療效和副效%Cochrane繫統評價
통심락효낭%료효화부효%Cochrane계통평개
Tongxinluo capsule%effect and adverse effect%Cochrane systematic review
背景通心络胶囊由5种虫类中药组成,主要用于心脑血管疾病.它于2000年获得国家科技进步二等奖,并被入国家中药基本药物.目的评价通心络胶囊治疗不稳定心绞痛的疗效和可能的副效.检索策略电子检索TheCochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register,publishedinthelatest issue of the Cochrane Library,MEDLINE,EMBASE,CBM,Chinese Cochrane Centre Controlled Trials Register,Current Con-troled Trials(www.controlled-trials.com),The National Research Register.手检我国83种中医药杂志.资料纳入标准使用通心络胶囊治疗不稳定性心绞痛的随机和半随机对照试验.结果测量指标为因急性心肌梗死所致的死亡、心绞痛的严重程度、急性心绞痛发作次数、心电图改善程度、硝酸甘油用量和症状改善,等等.资料分析对符合纳入标准的随机对照试验进行内部真实性评价,如果所有纳入的随机对照试验有足够的质量和相似性,则采用Meta分析.
揹景通心絡膠囊由5種蟲類中藥組成,主要用于心腦血管疾病.它于2000年穫得國傢科技進步二等獎,併被入國傢中藥基本藥物.目的評價通心絡膠囊治療不穩定心絞痛的療效和可能的副效.檢索策略電子檢索TheCochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register,publishedinthelatest issue of the Cochrane Library,MEDLINE,EMBASE,CBM,Chinese Cochrane Centre Controlled Trials Register,Current Con-troled Trials(www.controlled-trials.com),The National Research Register.手檢我國83種中醫藥雜誌.資料納入標準使用通心絡膠囊治療不穩定性心絞痛的隨機和半隨機對照試驗.結果測量指標為因急性心肌梗死所緻的死亡、心絞痛的嚴重程度、急性心絞痛髮作次數、心電圖改善程度、硝痠甘油用量和癥狀改善,等等.資料分析對符閤納入標準的隨機對照試驗進行內部真實性評價,如果所有納入的隨機對照試驗有足夠的質量和相似性,則採用Meta分析.
배경통심락효낭유5충충류중약조성,주요용우심뇌혈관질병.타우2000년획득국가과기진보이등장,병피입국가중약기본약물.목적평개통심락효낭치료불은정심교통적료효화가능적부효.검색책략전자검색TheCochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register,publishedinthelatest issue of the Cochrane Library,MEDLINE,EMBASE,CBM,Chinese Cochrane Centre Controlled Trials Register,Current Con-troled Trials(www.controlled-trials.com),The National Research Register.수검아국83충중의약잡지.자료납입표준사용통심락효낭치료불은정성심교통적수궤화반수궤대조시험.결과측량지표위인급성심기경사소치적사망、심교통적엄중정도、급성심교통발작차수、심전도개선정도、초산감유용량화증상개선,등등.자료분석대부합납입표준적수궤대조시험진행내부진실성평개,여과소유납입적수궤대조시험유족구적질량화상사성,칙채용Meta분석.
Background Tongxinluo capsule is a new drug for cardio- cerebral vascular diseases on the national essential drug list of China, and the second-class award of National Science and Technology Development of China, 2001. Objective This review aims to assess the effect (harms and benefits) of Tongxinluo capsule for unstable angina. Search strategy electronic searchs The Cochrane Heart Review Group specialised trials register,The Cochrane Controlled Trials Register, published in the latest issue of the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese Cochrane Centre Controlled Trials Register, Current Controlled Trials (www. controlled-trials. com), The National Research Register Handsearchs We will search 83 journals of Chinese traditional medicine. Inclusion riteria We will include randomised controlled trials of Tonxinluo capsule versus placebo or other current phamarcotherapy or other Chinese medicinal herbs in the participants with unstable angina pectoris. Studies will report mortality (sudden death from acute myocardial infarction), severity of angina pectoris, frequency of acute attack angina, ECG improvement, rate of dosage reducing or taking frequency of nitroglycerine and symptom improvement, etc. Data analysis Data will be included in a meta-analysis if they are available, of sufficient quality and sufficiently similar.
